Impact of COVID-19 pandemic on prostate cancer outcomes at an uro-oncology referral center

• Published in: International Brazilian Journal of Urology Vol. 49; no. 2; pp. 233 - 242
• Main Authors: Andrade, Guilherme Miranda, Sesconetto, Lucas, da Silva, Rafael Benjamim Rosa, Dos Santos, Gabriela Guimarães Rodrigues, Kayano, Paulo Priante, Baccaglini, Willy, Bezerra, Murilo Borges, Bianco, Bianca, Lemos, Gustavo Caserta, Carneiro, Arie
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Urologia 01.04.2023
• Subjects: COVID-19; COVID-19 - pathology; Humans; Male; Neoplasm Staging; Original; Pandemics; Prostate-Specific Antigen; Prostatectomy; Prostatectomy - methods; Prostatic Neoplasms; Prostatic Neoplasms - pathology; Retrospective Studies; COVID-19; Prostatic Neoplasms; Prostatectomy
• DOI: 10.1590/S1677-5538.IBJU.2022.0393
• ISSN: 1677-5538

To evaluate the possible effects of the coronavirus disease 2019 (COVID-19) pandemic on the oncologic results of patients with prostate cancer regarding clinical staging, presence of adverse pathological outcomes, and perioperative complications. This retrospective study included patients who underwent radical prostatectomy. The time between biopsy and surgery, staging tests, final histopathological evaluation after surgery, lymphadenectomy rate, postoperative complications, and prostatic specific antigen (PSA) levels (initial and 30 days after surgery) were analyzed and compared in a group of patients before and during the pandemic period. We included 226 patients: 88 in the pre-pandemic period and 138 during the pandemic period. There was no statistically significant difference in mean age, body mass index, ASA, pathological locally advanced disease, the proportion of patients who underwent lymphadenectomy, and ISUP grade in the biopsy between the groups. Positive surgical margins, prostatic extracapsular extension, and PSA levels at 30 days were also similar between the groups. The mean time between medical consultation and surgery was longer in the pandemic period than in the pre-pandemic (124 vs. 107 days, p<0.001), and the mean time between biopsy and medical consultation (69.5 days vs. 114 days, p<0.001) and between biopsy and surgery (198.5 days vs. 228 days, p=0.013) was shorter during the pandemic. The incidence of severe early and late perioperative complications was similar between the periods. There was no delay between diagnosis and treatment at our institution during the COVID-19 pandemic period. No worsening of the prostate cancer features was observed.